Welcome to LookChem.com Sign In|Join Free

CAS

  • or

868594-38-1

Post Buying Request

868594-38-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

868594-38-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 868594-38-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,8,5,9 and 4 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 868594-38:
(8*8)+(7*6)+(6*8)+(5*5)+(4*9)+(3*4)+(2*3)+(1*8)=241
241 % 10 = 1
So 868594-38-1 is a valid CAS Registry Number.

868594-38-1Relevant articles and documents

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

Kawamura, Shuhei,Ito, Yoshihiko,Hirokawa, Takatsugu,Hikiyama, Eriko,Yamada, Shizuo,Shuto, Satoshi

, p. 4020 - 4029 (2018/05/07)

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

Synthesis of bifunctional integrin-binding peptides containing PEG spacers of defined length for non-viral gene delivery

Pilkington-Miksa, Michael A.,Sarkar, Supti,Writer, Michele J.,Barker, Susie E.,Shamlou, Parviz Ayazi,Hart, Stephen L.,Hailes, Helen C.,Tabor, Alethea B.

experimental part, p. 2900 - 2914 (2009/04/11)

Improving the buffer and serum stability of non-viral gene delivery vectors, and increasing their circulation time in vivo, is an important focus of current research in gene therapy. The most successful strategies to date have involved shielding the complexes with large polydisperse PEG adducts. However, this approach is accompanied by a fall in transfection efficiency. In this paper we describe the solid-phase synthesis of a series of bifunctional peptides bearing short PEG spacers of defined structure as components of lipopolyplex gene delivery vectors. Short, high-yielding routes to a series of PEG-amino acids are described: these PEG-amino acids can be used in varying combinations to afford bifunctional peptides with varying lengths of PEG spacers by using standard solid-phase synthesis techniques. A series of lipopolyplexes were formulated using these bifunctional peptides, and their transfection properties assessed. Dynamic light scattering measurements on the complex with the best transfection properties showed that in phosphate-buffered saline this complex was considerably more stable, and aggregated more slowly, than a complex formulated using a similar peptide lacking the short PEG spacer. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 868594-38-1